Key Takeaway: Phio Pharmaceuticals has announced a significant patent milestone, securing additional protections for its INTASYL compounds in the United States, Canada, and Japan. This advancement is crucial for the company as it continues to develop its proprietary gene silencing technology aimed at eliminating cancer. The notices of allowance and grant decisions highlight the progress made in their clinical-stage biopharmaceutical efforts.
Price reaction · baseline $1.03 (2026-07-14 close) · hit pre-market · clean, no other PHIO news in the window
Patents granted in key markets: the United States, Canada, and Japan.
Progress in developing therapeutics for cancer treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~9 mo
Medium dilution risk
Lead asset
DP CD8 TIL
Phase 1 · HNSCC
Full Press Release Details
Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds King of Prussia, Pennsylvania–(Newsfile Corp. – July 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today significant progress in the […]
The post Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision appeared first on Phio Pharmaceuticals .
Frequently Asked Questions
What patent protections did Phio Pharmaceuticals secure?
Phio Pharmaceuticals secured patent protections for INTASYL compounds in the US, Canada, and Japan.
What technology does Phio Pharmaceuticals use?
Phio Pharmaceuticals uses its proprietary INTASYL® gene silencing technology.
What is the focus of Phio Pharmaceuticals' development?
Phio Pharmaceuticals is focused on developing therapeutics to eliminate cancer.
What is the significance of the patent milestone?
The patent milestone is significant as it enhances Phio's intellectual property protection and supports its clinical-stage efforts.